Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2027 earnings estimates for shares of Inspire Medical Systems in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn $3.57 per share for the year, down from their prior forecast of $3.63. The consensus estimate for Inspire Medical Systems' current full-year earnings is $1.33 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems' FY2028 earnings at $5.69 EPS.
Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, November 4th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.06 by $0.54. The firm had revenue of $203.20 million during the quarter, compared to analysts' expectations of $197.59 million. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. Inspire Medical Systems's revenue for the quarter was up 32.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.29) EPS.
INSP has been the subject of several other research reports. Truist Financial reiterated a "buy" rating and set a $240.00 price target (up previously from $217.00) on shares of Inspire Medical Systems in a report on Monday, September 30th. Stifel Nicolaus reiterated a "hold" rating and set a $200.00 target price (up previously from $170.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Piper Sandler restated an "overweight" rating and issued a $260.00 price target (up from $255.00) on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Robert W. Baird lifted their price target on Inspire Medical Systems from $240.00 to $252.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Finally, Bank of America upgraded Inspire Medical Systems from a "neutral" rating to a "buy" rating and increased their price objective for the company from $220.00 to $255.00 in a report on Wednesday, November 20th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $233.58.
Get Our Latest Stock Report on Inspire Medical Systems
Inspire Medical Systems Price Performance
Shares of INSP stock traded down $10.27 during trading hours on Tuesday, reaching $189.05. 421,607 shares of the stock were exchanged, compared to its average volume of 597,518. The business's fifty day moving average is $199.01 and its two-hundred day moving average is $175.73. The firm has a market capitalization of $5.67 billion, a P/E ratio of 176.68 and a beta of 1.36. Inspire Medical Systems has a 12-month low of $123.00 and a 12-month high of $257.40.
Insider Buying and Selling at Inspire Medical Systems
In other news, Director Shawn Mccormick sold 800 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the sale, the director now owns 23,140 shares in the company, valued at approximately $5,090,800. This represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.10% of the stock is owned by company insiders.
Institutional Trading of Inspire Medical Systems
Several institutional investors and hedge funds have recently added to or reduced their stakes in INSP. Price T Rowe Associates Inc. MD raised its position in Inspire Medical Systems by 51.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 459,766 shares of the company's stock worth $98,754,000 after buying an additional 156,893 shares during the last quarter. Bayesian Capital Management LP purchased a new position in Inspire Medical Systems during the first quarter worth about $504,000. Kennedy Capital Management LLC acquired a new stake in Inspire Medical Systems in the first quarter valued at about $2,207,000. Jacobs Levy Equity Management Inc. purchased a new stake in Inspire Medical Systems in the 1st quarter valued at approximately $4,514,000. Finally, Tidal Investments LLC acquired a new position in Inspire Medical Systems during the 1st quarter worth approximately $1,151,000. 94.91% of the stock is owned by hedge funds and other institutional investors.
About Inspire Medical Systems
(
Get Free Report)
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.
See Also
Before you consider Inspire Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.
While Inspire Medical Systems currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
